NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.18 +0.23 (+0.29%) GOLD FUTURES
2,312.70 +3.10 (+0.13%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,186.05 +600.94 (+1.29%)
MRNA Jan 2025 50.000 put
| Previous close | 0.6700 |
| Open | 0.6900 |
| Bid | 0.3500 |
| Ask | 0.4800 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.4500 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.21k |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
- Yahoo Finance Video
Moderna CEO on the changing COVID market: Pandemic to endemic
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market. As the coronavirus pandemic has shifted toward an endemic, Bancel explains how Moderna continues to innovate, sharing a positive outlook on phase two data for a combination flu and coronavirus vaccine. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Investor's Business DailyModerna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.
